Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Faecal calprotectin measurement predicts relapse in IBD patients under anti-TNF therapy

14 Feb 2018

In patients with inflammatory bowel disease (IBD) on maintenance therapy with antitumour necrosis factor (anti-TNF) drugs, faecal calprotectin (FC) appears to be a good predictor of clinical relapse as well as remission over the following 4 months, reports a recent study.

“FC levels <130 μg/g are consistently associated with maintained disease remission, whereas concentrations >300 μg/g allow predicting relapse with a high probability at any time over the following 4 months,” the authors said.

Of the 106 included patients, 95 completed the study and were thus analysed (median age 44 years; 50.5 percent female; 75 percent with Crohn’s disease).

There were 30 patients (31.6 percent) who had a relapse over follow-up. FC concentration was significantly greater in patients who relapsed (477 μg/g) as compared with those who maintained in remission (65 μg/g; p<0.005). The optimal cutoff was 130 μg/g for predicting remission (negative predictive value, 100 percent) and 300 μg/g for predicting relapse (positive predictive value, 78.3 percent).

To assess the accuracy of consecutive FC measurements in predicting flares, the authors designed a prospective longitudinal cohort study with 16-month follow-up period, which included IBD patients in clinical remission for at least 6 months under anti-TNF therapy.

Measurement of FC levels was conducted at 4-month intervals for 1 year, and patients were clinically examined for relapse at 2-month intervals. Receiver-operating characteristic curve analysis was used to assess the diagnostic accuracy of FC for predicting relapse.

“Predicting relapse in IBD patients could allow early changes in therapy,” according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 5 days ago
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Jairia Dela Cruz, 6 days ago
Male smokers under the age of 50 years are at risk of developing ischaemic stroke, and this risk increases with the number of cigarettes smoked daily, according to data from the Stroke Prevention in Young Men Study.
Yesterday
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.